Tips for Pharmaceutical Manufacturing Scale-Up & Tech Transfer

When a CMO or CDMO transfer takes place, there are observable symptoms or signals that manufacturing and quality control professionals should monitor. Recognizing these early red flags can mitigate risks…

As organizations scale up production, symptoms indicating potential issues with the comparability of products often emerge. These signals can manifest in various forms, including:Click to read the full article.

Recognizing early indicators of potential regulatory complications during scale-up can help in effectively managing the risk. Common symptoms may include:Click to read the full article.

During a routine production run of a biopharmaceutical product at a large manufacturing facility, operators observed several deviations from expected performance metrics. Key symptoms included:Click to read the full article.

Initial signs of issues during the scale-up process can often be subtle. In our case study, symptoms included:Click to read the full article.

Recognizing and interpreting the initial signals indicating issues with scale-up data alignment is crucial. Draw a connection between the operational problems encountered during scale-up and the regulatory filing impact they…

When a sterile product scale-up encounters issues, several symptoms may emerge, indicating potential regulatory concerns:Click to read the full article.

Identifying early signals of potential issues during sterile product scale-up is crucial for effective interventions. Common symptoms include:Click to read the full article.

Identifying symptoms that indicate potential regulatory filing impacts during biologics manufacturing is critical. Look for the following signals:Click to read the full article.

Identifying symptoms early is crucial to manage regulatory filing implications effectively. Common signals that suggest potential issues during scale-up may include:Click to read the full article.

It is essential to recognize the early symptoms that indicate a potential disconnect when scaling up production. Common signals may include:Click to read the full article.

During a routine internal audit, the Quality Assurance (QA) team discovered several anomalies during the manufacturing of a new oncology drug. Key observations that raised red flags included:Click to read…